Clinuvel is announcing more positive results with its trial of the melanin boosting drug afamelanotide for the disease polymorphic light eruption (PLE).
Even though this condition is rare and it is a stretch to say that treating rosacea with this drug is a given, it is still interesting to follow the development of this drug.
Today’s press release relate to the continuing good results, this time from the Phase III (randomised, double blind, placebo controlled) clinical trials.
The Rosacea Question
For those who do suffer from PLE, simple events like venturing outside can be a trauma. Environmental trauma is experienced by some rosacea sufferers so for them, developments like afamelanotide are interesting.
Just to what extent those with severe sun triggers will experience relief from afamelanotide is completely up for question. How easily rosacea sufferers will be able to be prescribed this drug is another open question.
Clinuvel announces PLE Phase III preliminary results
Friday 18th December 2009, Melbourne, Australia
Trial in polymorphic light eruption (PLE) to support the final registration dossier of afamelanotide
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has
obtained preliminary results in its multicenter randomised double-blind placebo controlled PLE study (CUV015) evaluating the safety and efficacy of afamelanotide 20 mg implants. PLE is a recurrent seasonal UV-related skin disorder seen mostly in fair-skinned patients (10-20% incidence) in the northern hemisphere.
1 comment so far ↓
Treatment, yes. Cure, no (sadly)
Leave a Comment